American Journal of Hematology

Article	Citations
Thrombocytopenia following Pfizer and Moderna SARS‐CoV‐2 vaccination	318
Multiple myeloma: 2022 update on diagnosis, risk stratification, and management	273
Thrombosis in COVID‐19	228
Polycythemia vera and essential thrombocythemia: 2021 update on diagnosis, risk‐stratification and management	217
Primary myelofibrosis: 2021 update on diagnosis, risk‐stratification and management	193
Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures	179
2021 Update on Diffuse large B cell lymphoma: A review of current data and potential applications on risk stratification and management	159
BNT162b2 COVID‐19 vaccine is significantly less effective in patients with hematologic malignancies	139
Age‐dependent and gender‐dependent antibody responses against SARS‐CoV‐2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine	129
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management	125
Efficacy and safety of CD19‐directed CAR‐T cell therapies in patients with relapsed/refractory aggressive B‐cell lymphomas: Observations from the JULIET, ZUMA	118
Intermediate‐dose anticoagulation, aspirin, and in‐hospital mortality in COVID‐19: A propensity score‐matched analysis	115
Prolonged in‐hospital stay and higher mortality after Covid‐19 among patients with non‐Hodgkin lymphoma treated with B‐cell depleting immunotherapy	108
Systemic mastocytosis in adults: 2021 Update on diagnosis, risk stratification and management	106
Acute myeloid leukemia: 2023 update on diagnosis, risk‐stratification, and management	98
Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study	96
Commercial anti‐CD19 CAR T cell therapy for patients with relapsed/refractory aggressive B cell lymphoma in a European center	94
Immune thrombocytopenia in a 22‐year‐old post Covid‐19 vaccine	89
Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring	88
Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients	84
Impact of sickle cell disease on patientsʼ daily lives, symptoms reported, and disease management strategies: Results from the international Sickle Cell World Assessment Survey (SWAY	81
POEMS syndrome: 2021 Update on diagnosis, risk‐stratification, and management	75
World Health Organization‐defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management	74
Acute myeloid leukemia: 2021 update on risk‐stratification and management	74
Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management	73

C3 inhibition with pegcetacoplan in subjects with paroxysmal nocturnal hemoglobinuria treated with eculizumab	71
Combination of CD19 and CD22 CAR‐T cell therapy in relapsed B‐cell acute lymphoblastic leukemia after allogeneic transplantation	69
Marked factor V activity elevation in severe COVID‐19 is associated with venous thromboembolism	69
Targeting BCL‐2 with venetoclax and dexamethasone in patients with relapsed/refractory t(11;14) multiple myeloma	65
Recommendations for diagnosis and treatment of methemoglobinemia	64
Venetoclax with decitabine vs intensive chemotherapy in acute myeloid leukemia: A propensity score matched analysis stratified by risk of treatment‐related mortality	62
Acute lymphoblastic leukemia: A population‐based study of outcome in the United States based on the surveillance, epidemiology, and end results (SEER) database, 1	57
Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment	56
SARS‐CoV‐2‐reactive antibody detection after SARS‐CoV‐2 vaccination in hematopoietic stem cell transplant recipients: Prospective survey from the Spanish Hematopoietic Stem Cell	56
Immune thrombocytopenia (ITP) World Impact Survey (I‐WISh): Impact of ITP on health‐related quality of life	56
Validated international definition of the thrombocytopenia, anasarca, fever, reticulin fibrosis, renal insufficiency, and organomegaly clinical subtype (TAFRO) of idiopathic multicentric Castlema	56
Waldenström macroglobulinemia: 2021 update on diagnosis, risk stratification, and management	54
Mantle cell lymphoma in 2022—A comprehensive update on molecular pathogenesis, risk stratification, clinical approach, and current and novel treatments	53
Hepcidin levels predict Covid‐19 severity and mortality in a cohort of hospitalized Italian patients	52
Increased blood viscosity and red blood cell aggregation in patients with COVID‐19	51
Increased sFLT‐1/PlGF ratio in COVID‐19: A novel link to angiotensin II‐mediated endothelial dysfunction	51
Outcome of T‐cell acute lymphoblastic leukemia/lymphoma: Focus on near‐ETP phenotype and differential impact of nelarabine	49
Immunoglobulin light chain amyloidosis: 2022 update on diagnosis, prognosis, and treatment	48
Ineffectiveness of high‐dose methotrexate for prevention of CNS relapse in diffuse large B‐cell lymphoma	48
Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases	46
Outcome of infection with omicron SARS‐CoV‐2 variant in patients with hematological malignancies: An EPICOVIDEHA survey report	46
Nelarabine as salvage therapy and bridge to allogeneic stem cell transplant in 118 adult patients with relapsed/refractory T‐cell acute lymphoblastic leukemia/lymphoma. A CAMPUS ALL study	45
Hypercoagulability, endotheliopathy, and inflammation approximating 1 year after recovery: Assessing the long‐term outcomes in COVID‐19 patients	44
Granulocyte‐colony stimulating factor in COVID‐19: Is it stimulating more than just the bone marrow?	43
Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management	42
Impact of spleen size and splenectomy on outcomes of allogeneic hematopoietic cell transplantation for myelofibrosis: A retrospective analysis by the chronic malignancies working party on behalf of Eu	42
Epidemiology, clinical picture and long‐term outcomes of FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia: Data from 151 patients	42
Late‐onset hematological complications post COVID‐19: An emerging medical problem for the hematologist	40
Whole blood viscosity and red blood cell adhesion: Potential biomarkers for targeted and curative therapies in sickle cell disease	40
Treatment‐free remission in patients with chronic myeloid leukemia following the discontinuation of tyrosine kinase inhibitors	40
Cerebral venous thrombosis post BNT162b2 mRNA SARS‐CoV‐2 vaccination: A black swan event	40
Roxadustat for the treatment of anemia in patients with lower‐risk myelodysplastic syndrome: Open‐label, dose‐selection, lead‐in stage of a phase 3 study	39
COVID‐19 vaccines and risks of hematological abnormalities: Nested case–control and self‐controlled case series study	39
2021 clinical trials update: Innovations in hemophilia therapy	38
2021 update on clinical trials in β‐thalassemia	38
Heparin induced thrombocytopenia antibodies in Covid‐19	37
High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicen	37
Prolonged hematologic toxicity following treatment with chimeric antigen receptor T cells in patients with hematologic malignancies	37
Moderate fixed‐dose hydroxyurea for primary prevention of strokes in Nigerian children with sickle cell disease: Final results of the SPIN trial	35
Real‐Life experience with hydroxyurea in patients with sickle cell disease: Results from the prospective ESCORT‐HU cohort study	35
Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping	34
First‐line treatment of double‐hit and triple‐hit lymphomas: Survival and tolerance data from a retrospective multicenter French study	33
The international consensus classification of myeloid neoplasms and acute Leukemias: myeloproliferative neoplasms	33
Myelodysplastic syndromes with ring sideroblasts (MDS‐RS) and MDS/myeloproliferative neoplasm with RS and thrombocytosis (MDS/MPN‐RS‐T) – “2021 u	32
Pregnancy outcomes with hydroxyurea use in women with sickle cell disease	31
EBV‐positive diffuse large B‐cell lymphoma, not otherwise specified: 2022 update on diagnosis, risk‐stratification, and management	31
Cell‐type‐specific insights into iron regulatory processes	31
Classification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach	31
Venetoclax combined with FLAG‐IDA induction and consolidation in newly diagnosed acute myeloid leukemia	31
Upgrading the evidence for the use of ambroxol in Gaucher disease and GBA related Parkinson: Investigator initiated registry based on real life data	30

Comparative effectiveness and safety of anticoagulants for the treatment of heparin‐induced thrombocytopenia	30
Impaired response to first SARS‐CoV‐2 dose vaccination in myeloproliferative neoplasm patients receiving ruxolitinib	30
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes	29
Comprehensive phenotyping of erythropoiesis in human bone marrow: Evaluation of normal and ineffective erythropoiesis	29
Follicular lymphoma: 2023 update on diagnosis and management	29
Laboratory testing for ADAMTS13: Utility for TTP diagnosis/exclusion and beyond	28
Recent advances in the pathophysiology of PIEZO1‐related hereditary xerocytosis	28
Hairy cell leukemia 2022: Update on diagnosis, risk‐stratification, and treatment	28
Phase I/II study of dasatinib in combination with decitabine in patients with accelerated or blast phase chronic myeloid leukemia	28
Anti‐CD19 and anti‐BCMA CAR T cell therapy followed by lenalidomide maintenance after autologous stem‐cell transplantation for high‐risk newly diagnosed multiple myeloma	27
Revisiting the non‐transfusion‐dependent (NTDT) vs. transfusion‐dependent (TDT) thalassemia classification 10 years later	27
Prediction of early (4‐week) mortality in acute myeloid leukemia with intensive chemotherapy	27
Randomized control trial of oral arginine therapy for children with sickle cell anemia hospitalized for pain in Nigeria	27
Persistence of Ad26.COV2.S‐associated vaccine‐induced immune thrombotic thrombocytopenia (VITT) and specific detection of VITT antibodies	27
Characterization of the rate, predictors, and thrombotic complications of thrombocytosis in iron deficiency anemia	27
Optical genome mapping for structural variation analysis in hematologic malignancies	27
Risk‐based, response‐adapted therapy for early‐stage extranodal nasal‐type NK/T‐cell lymphoma in the modern chemotherapy era: A China Lymphoma Collaborative Group study	27
Localized immunoglobulin light chain amyloidosis: Novel insights including prognostic factors for local progression	26
Treatment of acquired hemophilia A, a balancing act: results from a 27‐year Dutch cohort study	26
Gene therapies for transfusion dependent β‐thalassemia: Current status and critical criteria for success	26
Daratumumab‐lenalidomide‐dexamethasone vs standard‐of‐care regimens: Efficacy in transplant‐ineligible untreated myeloma	26
Outcomes of TP53‐mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival	26
Hodgkin lymphoma: 2023 update on diagnosis, risk‐stratification, and management	26
Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia	26
Large granular lymphocytic leukemia – A retrospective study of 319 cases	26
Chimeric antigen receptor T‐cells, bispecific antibodies, and antibody‐drug conjugates for multiple myeloma: An update	26
Treatment outcomes and prognostic factors of patients with adult Langerhans cell histiocytosis	26
Frontline combination of ponatinib and hyper‐CVAD in Philadelphia chromosome‐positive acute lymphoblastic leukemia: 80‐months follow‐up results	25
Myelodysplastic syndromes: 2023 update on diagnosis, risk‐stratification, and management	25
Basiliximab for steroid‐refractory acute graft‐versus‐host disease: A real‐world analysis	25
Cytogenetic and molecular abnormalities in Waldenström's macroglobulinemia patients: Correlations and prognostic impact	25
2021 Update on allogeneic hematopoietic stem cell transplant for myelofibrosis: A review of current data and applications on risk stratification and management	25
Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management	25
Familial thrombocytopenia flare‐up following the first dose of mRNA‐1273 Covid‐19 vaccine	25
Myeloproliferative neoplasms and pregnancy: Overview and practice recommendations	25
Current approaches to management of newly diagnosed multiple myeloma	24
Myeloid and lymphoid vacuolation in VEXAS syndrome	24
Polycythemia vera: 2024 update on diagnosis, risk‐stratification, and management	24
Treosulfan compared with reduced‐intensity busulfan improves allogeneic hematopoietic cell transplantation outcomes of older acute myeloid leukemia and myelodysplastic syndrome patients: Fi	24
Gilteritinib clinical activity in relapsed/refractory FLT3 mutated acute myeloid leukemia previously treated with FLT3 inhibitors	24
Fresh vs. frozen allogeneic peripheral blood stem cell grafts: A successful timely option	24
Serologic response to mRNA COVID‐19 vaccination in lymphoma patients	23
Venetoclax and hypomethylating agents in FLT3‐mutated acute myeloid leukemia	23
An artificial intelligence‐assisted diagnostic platform for rapid near‐patient hematology	23
Clinical and molecular predictors of fibrotic progression in essential thrombocythemia: A multicenter study involving 1607 patients	23
Risk factors for severe COVID‐19 in hospitalized sickle cell disease patients: A study of 319 patients in France	23
Adolescent and young adult acute lymphoblastic leukemia. Final results of the phase II pediatric‐like GIMEMA LAL‐1308 trial	23
Clinical outcomes after 4.5 years of eliglustat therapy for Gaucher disease type 1: Phase 3 ENGAGE trial final results	23
Reduced intensity conditioning allogeneic hematopoietic stem cell transplantation in VEXAS syndrome: Data from a prospective series of patients	23
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression‐free survival and early treatment failure af	23
The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations	23
Single‐agent cladribine as an effective front‐line therapy for adults with Langerhans cell histiocytosis	23
Aggressive T‐cell lymphomas: 2021 Updates on diagnosis, risk stratification and management	23
Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes	22
Lovo‐cel gene therapy for sickle cell disease: Treatment process evolution and outcomes in the initial groups of the HGB‐206 study	22
Phase 1 study of combinatorial sorafenib, G‐CSF, and plerixafor treatment in relapsed/refractory, FLT3‐ITD‐mutated acute myelogenous leukemia patients	22
Sequential P‐GEMOX and radiotherapy for early‐stage extranodal natural killer/T‐cell lymphoma: A multicenter study	22
Phase two study of crizotinib in patients with anaplastic lymphoma kinase (ALK)‐positive anaplastic large cell lymphoma relapsed/refractory to chemotherapy	22
Safety and efficacy of mitapivat, an oral pyruvate kinase activator, in sickle cell disease: A phase 2, open‐label study	22
Fecal microbiota transplantation in patients with acute and chronic graft‐versus‐host disease—spectrum of responses and safety profile. Results from a prospective, multicenter study	22
The impact of extended half‐life factor concentrates on prophylaxis for severe hemophilia in the United States	22
Reduced global cerebral oxygen metabolic rate in sickle cell disease and chronic anemias	22
Ultrasensitive NGS MRD assessment in Ph+ ALL: Prognostic impact and correlation with RT‐PCR for BCR::ABL1	21
Venetoclax for the treatment of multiple myeloma: Outcomes outside of clinical trials	21
The prognostic value of additional copies of 1q21 in multiple myeloma depends on the primary genetic event	21
Daratumumab for disabling cold agglutinin disease refractory to B‐cell directed therapy	21
SARS‐CoV‐2 vaccination in patients with autoimmune cytopenias: The experience of a reference center	21
The International Hemoglobinopathy Research Network (INHERENT): An international initiative to study the role of genetic modifiers in hemoglobinopathies	21
Successful treatment of thrombotic thrombocytopenia with cerebral sinus venous thrombosis following Ad26.COV2.S vaccination	21
Safety and efficacy of jaktinib in the treatment of Janus kinase inhibitor‐naïve patients with myelofibrosis: Results of a phase II trial	21
Oxygen gradient ektacytometry‐derived biomarkers are associated with vaso‐occlusive crises and correlate with treatment response in sickle cell disease	21
Viscoelastic hemostatic assays: Update on technology and clinical applications	21
Making hydroxyurea affordable for sickle cell disease in Tanzania is essential (HASTE): How to meet major health needs at a reasonable cost	21
Decitabine and vorinostat with FLAG chemotherapy in pediatric relapsed/refractory AML: Report from the therapeutic advances in childhood leukemia and lymphoma (TACL) c	20
Current approaches to management of high‐risk multiple myeloma	20
Venetoclax combinations induce high response rates in newly diagnosed acute myeloid leukemia patients ineligible for intensive chemotherapy in routine practice	20
TLR8/TLR7 dysregulation due to a novel TLR8 mutation causes severe autoimmune hemolytic anemia and autoinflammation in identical twins	20
Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID‐19)	20
Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment	20
Risk of mortality from anemia and iron overload in nontransfusion‐dependent β‐thalassemia	20

Insufficient evidence exists to use histopathologic subtype to guide treatment of idiopathic multicentric Castleman disease	20
Iron and platelets: A subtle, under‐recognized relationship	20
Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia	20
Vaccine‐induced thrombotic thrombocytopenia following Ad26.COV2.S vaccine in a man presenting as acute venous thromboembolism	19
The LEukemia Artificial Intelligence Program (LEAP) in chronic myeloid leukemia in chronic phase: A model to improve patient outcomes	19
Cytomegalovirus kinetics after hematopoietic cell transplantation reveal peak titers with differential impact on mortality, relapse and immune reconstitution	19
Langerhans cell histiocytosis with lung involvement in isolation and multisystem disease: Staging, natural history, and comparative survival	19
Targeting constitutively active STAT3 in chronic lymphocytic leukemia: A clinical trial of the STAT3 inhibitor pyrimethamine with pharmacodynamic analyses	19
Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25‐year longitudinal study	19
Outcome of adults with relapsed/refractory T‐cell acute lymphoblastic leukemia or lymphoblastic lymphoma	19
Hemolytic crisis due to Covid‐19 vaccination in a woman with cold agglutinin disease	19
An effective chemotherapy‐free regimen of ponatinib plus venetoclax for relapsed/refractory Philadelphia chromosome‐positive acute lymphoblastic leukemia	19
Intravenous high‐dose methotrexate based systemic therapy in the treatment of isolated primary vitreoretinal lymphoma: An LOC network study	19
Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years	19
Allogeneic hematopoietic cell transplantation in older myelofibrosis patients: A study of the chronic malignancies working party of EBMT and the Spanish Myelofibrosis Registry	19
Low‐dose dasatinib 50 mg/day versus standard‐dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis	19
A phase I clinical trial of avelumab in combination with decitabine as first line treatment of unfit patients with acute myeloid leukemia	18
Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions	18
Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open‐label study	18
BRD4 degradation blocks expression of MYC and multiple forms of stem cell resistance in Ph+ chronic myeloid leukemia	18
Characteristics of late transplant‐associated thrombotic microangiopathy in patients who underwent allogeneic hematopoietic stem cell transplantation	18
Systemic mastocytosis in adults: 2023 update on diagnosis, risk stratification and management	18
Decitabine and venetoclax for IDH1/2‐mutated acute myeloid leukemia	18
Diagnostic work‐up for severe aplastic anemia in children: Consensus of the North American Pediatric Aplastic Anemia Consortium	18
Overall survival of patients with triple‐class refractory multiple myeloma treated with selinexor plus dexamethasone vs standard of care in MAMMOTH	18
Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia	17
Differentiation syndrome with lower‐intensity treatments for acute myeloid leukemia	17
Individual red blood cell fetal hemoglobin quantification allows to determine protective thresholds in sickle cell disease	17
Momelotinib for myelofibrosis: 12‐year survival data and retrospective comparison to ruxolitinib	17
Venetoclax and hypomethylating agents in older/unfit patients with blastic plasmacytoid dendritic cell neoplasm	17
Adoptive therapy with cytomegalovirus‐specific T cells for cytomegalovirus infection after haploidentical stem cell transplantation and factors affecting efficacy	17
Comparison of the International Consensus and 5th WHO edition classifications of adult myelodysplastic syndromes and acute myeloid leukemia	17
Romidepsin and lenalidomide‐based regimens have efficacy in relapsed/refractory lymphoma: Combined analysis of two phase I studies with expansion cohorts	17
Splenectomy before allogeneic hematopoietic cell transplantation for myelofibrosis: A French nationwide study	17
CDKN2A deletions are associated with poor outcomes in 101 adults with T‐cell acute lymphoblastic leukemia	17
Tyrosine Kinase Inhibitor discontinuation in Chronic Myeloid Leukemia: eligibility criteria and predictors of success	17
Determination of fitness and therapeutic options in older patients with acute myeloid leukemia	17
The impact of granulocyte colony stimulating factor on patients receiving chimeric antigen receptor T‐cell therapy	17
Patient‐reported neurocognitive symptoms influence instrumental activities of daily living in sickle cell disease	17
Risk factors for severe infection and mortality In patients with COVID‐19 in patients with multiple myeloma and AL amyloidosis	17
Deciphering the individual contribution of absolute neutrophil and monocyte counts to thrombosis risk in polycythemia vera and essential thrombocythemia	17
Haploidentical vs matched unrelated donor transplantation for acute myeloid leukemia in remission: A prospective comparative study	17
A phase I/II study of ixazomib, pomalidomide, and dexamethasone for lenalidomide and proteasome inhibitor refractory multiple myeloma (Alliance A061202)	17
Cerebral venous thrombosis and myeloproliferative neoplasms: A three‐center study of 74 consecutive cases	16
Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T‐cell lymphoma in a Chinese population: A multicenter phase II trial	16
Severe thrombocytopenia and microangiopathic hemolytic anemia in pregnancy: A guide for the consulting hematologist	16
Waldenström macroglobulinemia: 2023 update on diagnosis, risk stratification, and management	16
Genetic screening of children with marrow failure. The role of primary Immunodeficiencies	16
JAK2 unmutated erythrocytosis: 2023 Update on diagnosis and management	16
Chimeric antigen receptor T‐cells safety: A pharmacovigilance and meta‐analysis study	16
Plasma P‐selectin is an early marker of thromboembolism in COVID‐19	16
Functional role of endothelial transferrin receptor 1 in iron sensing and homeostasis	16
Effect of age and frailty on the efficacy and tolerability of once‐weekly selinexor, bortezomib, and dexamethasone in previously treated multiple myeloma	16
Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen	16
The evaluation and management of monoclonal gammopathy of renal significance and monoclonal gammopathy of neurological significance	16
Multicenter evaluation of efficacy and toxicity of venetoclax‐based combinations in patients with accelerated and blast phase myeloproliferative neoplasms	15
A novel 4‐mRNA signature predicts the overall survival in acute myeloid leukemia	15
Survival analysis in treated plasmablastic lymphoma patients: a population‐based study	15
Cutaneous B‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management	15
Long‐term results of low‐intensity chemotherapy with clofarabine or cladribine combined with low‐dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukem	15
Sex differences in lymphoma incidence and mortality by subtype: A population‐based study	15
Refining amyloid complete hematological response: Quantitative serum free light chains superior to ratio	15
Improved outcomes among newly diagnosed patients with FMS‐like tyrosine kinase 3 internal tandem duplication mutated acute myeloid leukemia treated with contemporary therapy: Revisiting the	15
Orelabrutinib in relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma patients: Multi‐center, single‐arm, open‐label, phase 2 study	15
Low‐dose ponatinib is a good option in chronic myeloid leukemia patients intolerant to previous TKIs	15
Bispecific T‐cell engagers for treatment of multiple myeloma	15
Parenteral iron therapy and phosphorus homeostasis: A review	15
The impact of voxelotor treatment on leg ulcers in patients with sickle cell disease	14
Chronic neutrophilic leukemia: 2022 update on diagnosis, genomic landscape, prognosis, and management	14
Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first‐line therapy in multiple myeloma	14
Real‐world experience with luspatercept and predictors of response in myelodysplastic syndromes with ring sideroblasts	14
Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis	14
Clonal hematopoiesis in patients with Covid‐19 is stable and not linked to an aggravated clinical course	14
Frequency and severity of pregnancy complications in women with hereditary thrombotic thrombocytopenic purpura	14
Chromosome 1q21 aberrations identify ultra high‐risk myeloma with prognostic and clinical implications	14
Chronic myeloid leukemia without major molecular response after 2 years of treatment with tyrosine kinase inhibitor	14
Comparison of neutralizing antibody responses against SARS‐CoV‐2 in healthy volunteers who received the BNT162b2 mRNA or the AZD1222 vaccine: Should the second AZ	14
Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: A systematic review	14
Intravenous ferric derisomaltose for the treatment of iron deficiency anemia	14
Selinexor, bortezomib, and dexamethasone versus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by cytogenetic risk	14
Daratumumab, lenalidomide, and dexamethasone in systemic light‐chain amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21	14
Lymphocyte predominant cells of nodular lymphocyte predominant Hodgkin lymphoma interact with rosetting T cells in an immunological synapse	14
Predictors of anemia response to momelotinib therapy in myelofibrosis and impact on survival	14
Depression in adolescents and young adults with heavy menstrual bleeding in a referral clinic setting	14
Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real‐life campus CLL study	14
Validation of the prognostic significance of the 2022 European LeukemiaNet risk stratification system in intensive chemotherapy treated aged 18 to 65 years patients with de novo acute myelo	13
Prediction of survival with intensive chemotherapy in acute myeloid leukemia	13
Molecular and clinicopathologic characterization of pediatric histiocytoses	13
Fecal microbiota transplantation with ruxolitinib as a treatment modality for steroid‐refractory/dependent acute, gastrointestinal graft‐versus‐host disease: A case series	13
Marginally reduced maternal hepatic and splenic ferroportin under severe nutritional iron deficiency in pregnancy maintains systemic iron supply	13
Humanized CD19‐targeted chimeric antigen receptor T (CAR‐T) cells for relapsed/refractory pediatric acute lymphoblastic leukemia	13
A multicenter real‐life study on anticoagulant treatment with direct oral anticoagulants in patients with Ph‐negative myeloproliferative neoplasms	13
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients	13
Association of ABO/Rh with SARS‐CoV‐2 positivity: The role of race and ethnicity in a female cohort	13
Cutaneous T‐cell lymphomas: 2023 update on diagnosis, risk‐stratification, and management	13